Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Fast Track Articles
  5. Fast Track Article
image of Review Understanding of the many Facets of Cancer and the Management of Skin Cancer
file format pdf download PDF

Abstract

Cancer is a complex disorder characterized by the unregulated proliferation of cells that have the potential to invade other regions of the body. It stems from genetic alterations in various cell types, resulting in tumor formation. These growths are classified as benign [noncancerous] or malignant [cancerous]. Unlike benign tumors, which typically remain localized, malignant tumors can spread, infiltrate nearby tissues, and establish secondary growth in organs far from the original site. The treatment approach depends on the specific type and progression of cancer, encompassing options such as surgical intervention, radiation-based therapies, drug-based treatments, immune system-boosting techniques, and therapies targeting particular cellular mechanisms. Skin cancer is a common occurrence among various cancer types, especially in populations with lighter skin tones. Skin cancer is a prevalent form of cancer, particularly in the Caucasian population. The most common skin cancers are basal cell carcinoma [BCC], squamous cell carcinoma [SCC], and melanoma. BCCs, which arise from the basal layer of the epidermis, are often treated with surgery, topical therapies, or cryotherapy depending on their risk and location. Mohs micrographic surgery is effective for high-risk or recurrent BCCs, whereas topical treatments such as 5-fluorouracil and imiquimod are used for superficial BCCs. Early diagnosis through biopsy and various imaging techniques is crucial for effective management. Advances in treatment, including targeted therapies and improved surgical techniques, continue to enhance patient outcomes and reduce recurrence rates. Understanding these diverse aspects of cancer and skin cancer will help devise effective treatment strategies and improve patient prognosis.

© 2024 The Author(s). Published by Bentham Science.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X350515241208061724
2024-12-12
2025-01-19

  • From This Site

    /content/journals/cis/10.2174/012210299X350515241208061724
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/10.2174/012210299X350515241208061724/e2210299X350515.html?itemId=/content/journals/cis/10.2174/012210299X350515241208061724&mimeType=html&fmt=ahah

References

  1. What Is Cancer? - NCI. 2023 Available from: https://www.cancer.gov/about-cancer/understanding/what-is-cancer (Accessed on: 7 May 2023).
  2. Cancer. 2023 Available from: https://www.who.int/news-room/fact-sheets/detail/cancer (Accessed on: 7 May 2023).
  3. Cancer Staging - NCI. 2023 Available from: https://www.cancer.gov/about-cancer/diagnosis-staging/staging (Accessed on: 7 May 2023).
  4. Treatment by Cancer Type. 2023 Available from: https://www.nccn.org/guidelines/category_1 (Accessed on: 7 May 2023).
  5. Padala S.A. Barsouk A. Thandra K.C. Saginala K. Mohammed A. Vakiti A. Epidemiology of renal cell carcinoma. World J. Oncol. 2020 11 3 79 87 10.14740/wjon1279 32494314
    [Google Scholar]
  6. Grünewald T.G.P. Alonso M. Avnet S. Banito A. Burdach S. Cidre-Aranaz F. Di Pompo G. Distel M. Dorado-Garcia H. Garcia-Castro J. González-González L. Grigoriadis A.E. Kasan M. Koelsche C. Krumbholz M. Lecanda F. Lemma S. Longo D.L. Madrigal-Esquivel C. Morales-Molina Á. Musa J. Ohmura S. Ory B. Pereira-Silva M. Perut F. Rodriguez R. Seeling C. Al Shaaili N. Shaabani S. Shiavone K. Sinha S. Tomazou E.M. Trautmann M. Vela M. Versleijen-Jonkers Y.M.H. Visgauss J. Zalacain M. Schober S.J. Lissat A. English W.R. Baldini N. Heymann D. Sarcoma treatment in the era of molecular medicine. EMBO Mol. Med. 2020 12 11 e11131 10.15252/emmm.201911131 33047515
    [Google Scholar]
  7. Devine S.M. Larson R.A. Acute leukemia in adults: recent developments in diagnosis and treatment. CA Cancer J. Clin. 1994 44 6 326 352 10.3322/canjclin.44.6.326 7953914
    [Google Scholar]
  8. Brigle K. Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin. Oncol. Nurs. 2017 33 3 225 236 10.1016/j.soncn.2017.05.012 28688533
    [Google Scholar]
  9. Carcinoma: Types, Treatment & What it Is. 2022 Available from: https://my.clevelandclinic.org/health/diseases/23180-carcinoma (Accessed on: 05/31/2022).
  10. What is Carcinoma? Metastatic, In Situ & Invasive | CTCA | City of Hope. 2022 Available from: https://www.cancercenter.com/carcinoma (Accessed on: 04/29/2022).
  11. Skin cancer is the 17th most common cancer worldwide. It is the 14th most common cancer in men and the 14th most common cancer in women. 2022 Available from: https://www.wcrf.org/cancer-trends/skin-cancer-statistics/
  12. Cullen J.K. Simmons J.L. Parsons P.G. Boyle G.M. Topical treatments for skin cancer. Advanced Drug Delivery Reviews. Elsevier B.V. 2020 Vol. 153 54 64
    [Google Scholar]
  13. Bonilla X. Parmentier L. King B. Bezrukov F. Kaya G. Zoete V. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat. Genet. 2016 48 4 398 406 10.1038/ng.3525
    [Google Scholar]
  14. Pandeya N. Olsen C.M. Whiteman D.C. The incidence and multiplicity rates of keratinocyte cancers in Australia. Med. J. Aust. 2017 207 8 339 343 10.5694/mja17.00284 29020905
    [Google Scholar]
  15. Green A.C. Olsen C.M. Cutaneous squamous cell carcinoma: an epidemiological review. Br. J. Dermatol. 2017 177 2 373 381 10.1111/bjd.15324 28211039
    [Google Scholar]
  16. Scopus preview - Scopus - Welcome to Scopus. 2023 Available from: https://www.scopus.com/home.uri
  17. Waseh S. Lee J.B. Advances in melanoma: epidemiology, diagnosis, and prognosis. Front. Med. (Lausanne) 2023 10 1268479 10.3389/fmed.2023.1268479 38076247
    [Google Scholar]
  18. Swetter S.M. Tsao H. Bichakjian C.K. Curiel-Lewandrowski C. Elder D.E. Gershenwald J.E. Guild V. Grant-Kels J.M. Halpern A.C. Johnson T.M. Sober A.J. Thompson J.A. Wisco O.J. Wyatt S. Hu S. Lamina T. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol. 2019 80 1 208 250 10.1016/j.jaad.2018.08.055 30392755
    [Google Scholar]
  19. Bichakjian C.K. Halpern A.C. Johnson T.M. Foote Hood A. Grichnik J.M. Swetter S.M. Tsao H. Barbosa V.H. Chuang T.Y. Duvic M. Ho V.C. Sober A.J. Beutner K.R. Bhushan R. Smith Begolka W. Guidelines of care for the management of primary cutaneous melanoma. J. Am. Acad. Dermatol. 2011 65 5 1032 1047 10.1016/j.jaad.2011.04.031 21868127
    [Google Scholar]
  20. Kim D.P. Kus K.J.B. Ruiz E. Basal Cell Carcinoma Review. Saunders W.B. Hematology/Oncology Clinics of North America. 2019 33 13 24 10.1016/j.hoc.2018.09.004
    [Google Scholar]
  21. Mason RS Reichrath J Sunlight vitamin D and skin cancer. Anticancer Agents Med. Chem. 2013 13 1 83 97 23094924
    [Google Scholar]
  22. Allen H. Skin cancer. Tadman M. Roberts D. Foulkes M. Tadman M. Roberts D. Foulkes M. Oxford Handbook of Cancer Nursing. Oxford University Press 2019 3 34 10.1093/med/9780198701101.003.0034
    [Google Scholar]
  23. Linares M.A. Zakaria A. Nizran P. Skin Cancer. Prim. Care 2015 42 4 645 659 10.1016/j.pop.2015.07.006 26612377
    [Google Scholar]
  24. Ahmed B. Qadir M.I. Ghafoor S. Malignant melanoma: Skin cancer—diagnosis, prevention, and treatment. Crit. Rev. Eukaryot. Gene Expr. 2020 30 4 291 297 10.1615/CritRevEukaryotGeneExpr.2020028454 32894659
    [Google Scholar]
  25. Dildar M. Akram S. Irfan M. Khan H.U. Ramzan M. Mahmood A.R. Alsaiari S.A. Saeed A.H.M. Alraddadi M.O. Mahnashi M.H. Skin cancer detection: A review using deep learning techniques. Int. J. Environ. Res. Public Health 2021 18 10 5479 10.3390/ijerph18105479 34065430
    [Google Scholar]
  26. Peris K. Fargnoli M.C. Garbe C. Kaufmann R. Bastholt L. Seguin N.B. Bataille V. Marmol V. Dummer R. Harwood C.A. Hauschild A. Höller C. Haedersdal M. Malvehy J. Middleton M.R. Morton C.A. Nagore E. Stratigos A.J. Szeimies R.M. Tagliaferri L. Trakatelli M. Zalaudek I. Eggermont A. Grob J.J. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. Eur. J. Cancer 2019 118 10 34 10.1016/j.ejca.2019.06.003 31288208
    [Google Scholar]
  27. Basset-Seguin N. Herms F. Update on the management of basal cell carcinoma. Acta Dermato-Venereologica. Medical Journals/Acta D-V 2020 100 284 290 10.2340/00015555‑3495
    [Google Scholar]
  28. Dorrell D.N. Strowd L.C. Skin cancer detection technology. Dermatol. Clin. 2019 37 4 527 536 10.1016/j.det.2019.05.010 31466592
    [Google Scholar]
  29. Greenwood J.D. Merry S.P. Boswell C.L. Skin biopsy techniques. Prim. Care 2022 49 1 1 22 10.1016/j.pop.2021.10.001 35125151
    [Google Scholar]
  30. Bauer J. Büttner P. Luther H. Wiecker T.S. Möhrle M. Garbe C. Blue light phototherapy of neonatal jaundice does not increase the risk for melanocytic nevus development. Arch. Dermatol. 2004 140 4 493 494 10.1001/archderm.140.4.493 15096388
    [Google Scholar]
  31. Hass H.G. Schmidt A. Nehls O. Kaiser S. DNA ploidy, proliferative capacity and intratumoral heterogeneity in primary and recurrent head and neck squamous cell carcinomas (HNSCC) – Potential implications for clinical management and treatment decisions. Oral Oncol. 2008 44 1 78 85 10.1016/j.oraloncology.2006.12.013 17350326
    [Google Scholar]
  32. Leon R. Martinez-Vega B. Fabelo H. Ortega S. Melian V. Castaño I. Carretero G. Almeida P. Garcia A. Quevedo E. Hernandez J.A. Clavo B. M Callico G. Non-invasive skin cancer diagnosis using hyperspectral imaging for in-situ clinical support. J. Clin. Med. 2020 9 6 1662 10.3390/jcm9061662 32492848
    [Google Scholar]
  33. Christensen-Jeffries K. Couture O. Dayton P.A. Eldar Y.C. Hynynen K. Kiessling F. O’Reilly M. Pinton G.F. Schmitz G. Tang M.X. Tanter M. van Sloun R.J.G. Super-resolution ultrasound imaging. Ultrasound Med. Biol. 2020 46 4 865 891 10.1016/j.ultrasmedbio.2019.11.013 31973952
    [Google Scholar]
  34. Daniel H. Gonzalez Maglio Eliana M. Cela Leoni Juliana Mariela L. Paz Cyclooxygenase-2 overexpression in non-melanoma skin cancer: Molecular pathways involved as targets for prevention and treatment. Skin Cancers - Risk Factors, Prevention and Therapy INTECH Open Access Publisher 2011 26355 10.5772/26355
    [Google Scholar]
  35. Huang H.Y. Hsiao Y.P. Karmakar R. Mukundan A. Chaudhary P. Hsieh S.C. Wang H.C. A review of recent advances in computer-aided detection methods using hyperspectral imaging engineering to detect skin cancer. Cancers (Basel) 2023 15 23 5634 10.3390/cancers15235634 38067338
    [Google Scholar]
  36. Goyal R. Husain S. Wilson K. Chopra H. Pahwa R. Loganathan M. Recent advancements in skin cancer treatment: a critical review. NPJ Digit Med. 2023 6 1 90 10.37349/emed.2023.00178
    [Google Scholar]
  37. Desai V.M. Kumbhar P. Kadam A.Y. Swarup J. Priya S. Jain A. Singhvi G. Exploring the therapeutic modalities of targeted treatment approach for skin carcinoma: cutting-edge strategies and key insights. Expert Opin. Drug Deliv. 2024 21 8 1213 1233 10.1080/17425247.2024.2392799 39136542
    [Google Scholar]
  38. Smak Gregoor A.M. Sangers T.E. Bakker L.J. Hollestein L. Uyl - de Groot C.A. Nijsten T. Wakkee M. An artificial intelligence based app for skin cancer detection evaluated in a population based setting. NPJ Digit. Med. 2023 6 1 90 10.1038/s41746‑023‑00831‑w 37210466
    [Google Scholar]
  39. Abobaker M. Govender M. Choonara Y.E. Non-surgical synergistic interventions for the treatment of skin cancer. Curr. Pharm. Des. 2024 30 10.2174/0113816128298264240530061039 38910485
    [Google Scholar]
  40. Quazi S.J. Aslam N. Saleem H. Rahman J. Khan S. Surgical margin of excision in basal cell carcinoma: a systematic review of literature. Cureus 2020 12 7 e9211 10.7759/cureus.9211 32821563
    [Google Scholar]
  41. van Loo E. Mosterd K. Krekels G.A.M. Roozeboom M.H. Ostertag J.U. Dirksen C.D. Steijlen P.M. Neumann H.A.M. Nelemans P.J. Kelleners-Smeets N.W.J. Surgical excision versus Mohs’ micrographic surgery for basal cell carcinoma of the face: A randomised clinical trial with 10year follow-up. Eur. J. Cancer 2014 50 17 3011 3020 10.1016/j.ejca.2014.08.018 25262378
    [Google Scholar]
  42. Talbot S. Hitchcock B. Incomplete primary excision of cutaneous basal and squamous cell carcinomas in the Bay of Plenty. N. Z. Med. J. 2004 117 1192 U848 15107870
    [Google Scholar]
  43. Masud D. Moustaki M. Staruch R. Dheansa B. Basal cell carcinomata: Risk factors for incomplete excision and results of re-excision. J. Plast. Reconstr. Aesthet. Surg. 2016 69 5 652 656 10.1016/j.bjps.2015.12.024 26948998
    [Google Scholar]
  44. Silverman M.K. Kopf A.W. Grin C.M. Bart R.S. Levenstein M.J. Recurrence rates of treated basal cell carcinomas. Part 2: Curettage-electrodesiccation. J. Dermatol. Surg. Oncol. 1991 17 9 720 726 10.1111/j.1524‑4725.1991.tb03425.x 1820764
    [Google Scholar]
  45. Goldman G. The current status of curettage and electrodesiccation. Dermatol. Clin. 2002 20 3 569 578, ix 10.1016/S0733‑8635(02)00022‑0 12170889
    [Google Scholar]
  46. Champeau M. Vignoud S. Mortier L. Mordon S. Photodynamic therapy for skin cancer: How to enhance drug penetration? J. Photochem. Photobiol. B 2019 197 June 111544 10.1016/j.jphotobiol.2019.111544 31295716
    [Google Scholar]
  47. Stoll A. van Oepen A. Friebe M. Intraoperative delivery of cell-killing boost radiation – a review of current and future methods. Minim. Invasive Ther. Allied Technol. 2016 25 4 176 187 10.3109/13645706.2016.1173563 27161210
    [Google Scholar]
  48. Tom M.C. Joshi N. Vicini F. Chang A.J. Hong T.S. Showalter T.N. Chao S.T. Wolden S. Wu A.J. Martin D. Husain Z. Badiyan S.N. Kolar M. Sherertz T. Mourtada F. Cohen G.N. Shah C. The american brachytherapy society consensus statement on intraoperative radiation therapy. Brachytherapy 2019 18 3 242 257 10.1016/j.brachy.2019.01.015 31084904
    [Google Scholar]
  49. Morton C.A. Dominicus R. Radny P. Dirschka T. Hauschild A. Reinhold U. Aschoff R. Ulrich M. Keohane S. Ekanayake-Bohlig S. Ibbotson S. Ostendorf R. Berking C. Gröne D. Schulze H.J. Ockenfels H.M. Jasnoch V. Kurzen H. Sebastian M. Stege H. Staubach P. Gupta G. Hübinger F. Ziabreva I. Schmitz B. Gertzmann A. Lübbert H. Szeimies R.M. A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. Br. J. Dermatol. 2018 179 2 309 319 10.1111/bjd.16441 29432644
    [Google Scholar]
  50. Jansen M.H.E. Mosterd K. Arits A.H.M.M. Roozeboom M.H. Sommer A. Essers B.A.B. van Pelt H.P.A. Quaedvlieg P.J.F. Steijlen P.M. Nelemans P.J. Kelleners-Smeets N.W.J. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J. Invest. Dermatol. 2018 138 3 527 533 10.1016/j.jid.2017.09.033 29045820
    [Google Scholar]
  51. Gutzmer R. Solomon J.A. Hedgehog pathway inhibition for the treatment of basal cell carcinoma. Target. Oncol. 2019 14 3 253 267 10.1007/s11523‑019‑00648‑2 31243642
    [Google Scholar]
  52. Pak E. Segal R.A. Hedgehog signal transduction: key players, oncogenic drivers, and cancer therapy. Dev. Cell 2016 38 4 333 344 10.1016/j.devcel.2016.07.026 27554855
    [Google Scholar]
  53. Villani A. Potestio L. Fabbrocini G. Scalvenzi M. New Emerging treatment options for advanced basal cell carcinoma and squamous cell carcinoma. Advances in Therapy. Adis 2022 39 1164 1178
    [Google Scholar]
  54. Williams H.C. Bath-Hextall F. Ozolins M. Armstrong S.J. Colver G.B. Perkins W. Miller P.S.J. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the sins randomized controlled trial. J. Invest. Dermatol. 2017 137 3 614 619 10.1016/j.jid.2016.10.019 27932240
    [Google Scholar]
  55. CHMP. Annex I summary of product characteristics. 2021 Available from: https://ec.europa.eu/health/documents/community-register/2021/20210223151110/anx_151110_en.pdf
  56. Kaatz M. Mohr P. Livingstone E. Weichenthal M. Kreuter A. Pföhler C. Leiter U. Ulrich J. Utikal J.S. Gutzmer R. Herbst R. Schadendorf D. Effectiveness, safety and utilization of vismodegib for locally advanced basal cell carcinoma under real-world conditions: non-interventional cohort study JONAS. Acta Derm. Venereol. 2022 102 adv00695 10.2340/actadv.v102.293 35199180
    [Google Scholar]
  57. Villani A. Fabbrocini G. Scalvenzi M. Sonidegib‐induced muscle spasms in the treatment of basal cell carcinoma: Strategies to adopt. Dermatol. Ther. 2022 35 7 10.1111/dth.15531
    [Google Scholar]
  58. Rubatto M. Sciamarrelli N. Borriello S. Pala V. Mastorino L. Tonella L. Ribero S. Quaglino P. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. Front. Med. (Lausanne) 2023 9 959289 10.3389/fmed.2022.959289 36844955
    [Google Scholar]
  59. Dachani S.R. Kaleem M. Mujtaba M.A. Mahajan N. Ali S.A. Almutairy A.F. Mahmood D. Anwer M.K. Ali M.D. Kumar S. A comprehensive review of various therapeutic strategies for the management of skin cancer. ACS Omega 2024 9 9 10030 10048 10.1021/acsomega.3c09780 38463249
    [Google Scholar]
  60. Saeed W. Shahbaz E. Maqsood Q. Ali S.W. Mahnoor M. Cutaneous oncology: strategies for melanoma prevention, diagnosis, and therapy. Cancer Contr. 2024 31 10732748241274978 10.1177/10732748241274978 39133519
    [Google Scholar]
  61. Bhadouria N. Alam A. Kaur A. Unraveling skin carcinoma: a comprehensive examination of diagnosis, treatment strategies, and emerging therapeutic avenues in skin cancer management. Pharm. Nanotechnol. 2024 12 1 16 10.2174/0122117385282163240220072251 38468531
    [Google Scholar]
  62. Zeng L. Gowda B.H.J. Ahmed M.G. Abourehab M.A.S. Chen Z.S. Zhang C. Advancements in nanoparticle-based treatment approaches for skin cancer therapy. Mol. Cancer 2023 22 1 10 10.1186/s12943‑022‑01708‑4 36635761
    [Google Scholar]
  63. Sol S. Boncimino F. Todorova K. Waszyn S.E. Mandinova A. Therapeutic approaches for non-melanoma skin cancer: standard of care and emerging modalities. Int. J. Mol. Sci. 2024 25 13 7056 10.3390/ijms25137056 39000164
    [Google Scholar]
  64. Wilken R. Criscito M. Pavlick A.C. Stevenson M.L. Carucci J.A. Current research in melanoma and aggressive nonmelanoma skin cancer. Facial Plast. Surg. 2020 36 2 200 210 10.1055/s‑0040‑1709118 32413929
    [Google Scholar]
  65. Ma V.T. Haring C.T. Warrier G. Swiecicki P.L. Targeted therapy and traditional chemotherapy in melanoma and cutaneous squamous cell carcinoma. Facial Plast. Surg. 2020 36 2 186 193 10.1055/s‑0040‑1709126 32413927
    [Google Scholar]
  66. Park K.K. Chun K.S. Lee J.M. Lee S.S. Surh Y.J. Inhibitory effects of [6]-gingerol, a major pungent principle of ginger, on phorbol ester-induced inflammation, epidermal ornithine decarboxylase activity and skin tumor promotion in ICR mice. Cancer Lett. 1998 129 2 139 144 10.1016/S0304‑3835(98)00081‑0 9719454
    [Google Scholar]
  67. Lipson E.J. Lilo M.T. Ogurtsova A. Esandrio J. Xu H. Brothers P. Schollenberger M. Sharfman W.H. Taube J.M. Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J. Immunother. Cancer 2017 5 1 23 10.1186/s40425‑017‑0228‑3 28344809
    [Google Scholar]
  68. Camacho-Barquero L. Villegas I. Sánchez-Calvo J.M. Talero E. Sánchez-Fidalgo S. Motilva V. Alarcón de la Lastra C. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int. Immunopharmacol. 2007 7 3 333 342 10.1016/j.intimp.2006.11.006 17276891
    [Google Scholar]
  69. Boroumand N Samarghandian S Hashemy SI Immunomodulatory, anti-inflammatory, and antioxidant effects of curcumin. J. HerbMed Pharmacol. Nickan Research Institute 2018 7 211 219 10.15171/jhp.2018.33
    [Google Scholar]
  70. Hosseini A. Alavi M.S. Ghane Nikookar Toos M. Jamialahmadi T. Sahebkar A. 6-Gingerol, an ingredient of Zingiber officinale, abrogates lipopolysaccharide-induced cardiomyocyte injury by reducing oxidative stress and inflammation. J. Agric. Food Res. 2024 15 101034 10.1016/j.jafr.2024.101034
    [Google Scholar]
  71. Frondoza C.G. Sohrabi A. Polotsky A. Phan P.V. Hungerford D.S. Lindmark L. An in vitro screening assay for inhibitors of proinflammatory mediators in herbal extracts using human synoviocyte cultures. In Vitro Cell Dev. Biol. Anim. 2004 40 3-4 95 101 10.1290/1543‑706x(2004)040<0095:aivsaf>2.0.co;2 15311968
    [Google Scholar]
  72. Gulec M. Iraz M. Yilmaz H.R. Ozyurt H. Temel I. The effects of ginkgo biloba extract on tissue adenosine deaminase, xanthine oxidase, myeloperoxidase, malondialdehyde, and nitric oxide in cisplatin-induced nephrotoxicity. Toxicol. Ind. Health 2006 22 3 125 130 10.1191/0748233705th255oa 16716042
    [Google Scholar]
  73. Yalçın E. Çavuşoğlu K. Acar A. Yapar K. In vivo protective effects of Ginkgo biloba L. leaf extract against hydrogen peroxide toxicity: cytogenetic and biochemical evaluation. Environ. Sci. Pollut. Res. Int. 2020 27 3 3156 3164 10.1007/s11356‑019‑07156‑w 31838678
    [Google Scholar]
  74. Ahsan H Reagan-Shaw S Eggert DM Tan TC Afaq F Mukhtar H Protective effect of sanguinarine on ultraviolet B-mediated damages in SKH-1 hairless mouse skin: Implications for prevention of skin cancer. Photochem. Photobiol. 2007 83 4 986 993 10.1111/j.1751‑1097.2007.00156.x
    [Google Scholar]
  75. Lambert J.D. An evidence-based perspective of camellia sinensis (green tea) for cancer patients. Evid-based Antican. Materia. Medica. 2011 349 373 10.1007/978‑94‑007‑0526‑5_16
    [Google Scholar]
  76. Yang C.S. Yang G.Y. Landau J.M. Kim S. Liao J. Tea and tea polyphenols inhibit cell hyperproliferation, lung tumorigenesis, and tumor progression. Experimental Lung Research. Informa Healthcare 1998 629 639 10.3109/01902149809087391
    [Google Scholar]
  77. Kulkarni S.K. Dhir A. Withania somnifera: An Indian ginseng. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 32 5 1093 1105 10.1016/j.pnpbp.2007.09.011 17959291
    [Google Scholar]
  78. Singh G. Sharma P.K. Dudhe R. Singh S. Biological activities of Withania somnifera. 2010 Available from: www.scholarsresearchlibrary.com
  79. Lebas E. Marchal N. Rorive A. Nikkels A.F. Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Expert Rev. Anticancer Ther. 2021 21 4 355 363 10.1080/14737140.2021.1876567 33554680
    [Google Scholar]
  80. Villani A. Ocampo-Garza S.S. Potestio L. Fabbrocini G. Ocampo-Candiani J. Ocampo-Garza J. Scalvenzi M. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin. Drug Saf. 2022 21 1 21 29 10.1080/14740338.2022.1993819 34644510
    [Google Scholar]
  81. Hughes B.G.M. Munoz-Couselo E. Mortier L. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann. Oncol. 2021 32 10 1276 1285 10.1016/j.annonc.2021.07.008 34293460
    [Google Scholar]
  82. Wolchok J.D. Kluger H. Callahan M.K. Postow M.A. Rizvi N.A. Lesokhin A.M. Segal N.H. Ariyan C.E. Gordon R.A. Reed K. Burke M.M. Caldwell A. Kronenberg S.A. Agunwamba B.U. Zhang X. Lowy I. Inzunza H.D. Feely W. Horak C.E. Hong Q. Korman A.J. Wigginton J.M. Gupta A. Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013 369 2 122 133 10.1056/NEJMoa1302369 23724867
    [Google Scholar]
  83. Postow M.A. Chesney J. Pavlick A.C. Robert C. Grossmann K. McDermott D. Linette G.P. Meyer N. Giguere J.K. Agarwala S.S. Shaheen M. Ernstoff M.S. Minor D. Salama A.K. Taylor M. Ott P.A. Rollin L.M. Horak C. Gagnier P. Wolchok J.D. Hodi F.S. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 2015 372 21 2006 2017 10.1056/NEJMoa1414428 25891304
    [Google Scholar]
  84. Marconcini R. Fava P. Nuzzo A. Manacorda S. Ferrari M. De Rosa F. De Tursi M. Tanda E.T. Consoli F. Minisini A. Pimpinelli N. Morgese F. Bersanelli M. Tucci M. Saponara M. Parisi A. Ocelli M. Bazzurri S. Massaro G. Morganti R. Ciardetti I. Stanganelli I. Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study. Front. Oncol. 2022 12 917999 10.3389/fonc.2022.917999 36046043
    [Google Scholar]
  85. Teo J.J. Nossier R. Chauhan A. Tan T.Z. Nga V.D.W. AB050. Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: A systematic review & network meta-analysis. Linchuang Zhongliuxue Zazhi 2024 13 Suppl. 1 AB050 10.21037/cco‑24‑ab050
    [Google Scholar]
  86. Merola J.P. Ocen J. Kumar S. Powell J. Hayhurst C. Survival in melanoma brain metastases in the era of novel systemic therapies. Neurooncol. Adv. 2020 2 1 vdaa144 10.1093/noajnl/vdaa144 33392503
    [Google Scholar]
  87. Badami S. Upadhaya S. Velagapudi R.K. Mikkilineni P. Kunwor R. Al Hadidi S. Bachuwa G. Clinical and molecular characteristics associated with survival in advanced melanoma treated with checkpoint inhibitors. J. Oncol. 2018 2018 1 1 13 10.1155/2018/6279871 30112001
    [Google Scholar]
  88. Mahdiabadi S. Momtazmanesh S. Karimi A. Rezaei N. Immune checkpoint inhibitors in advanced cutaneous melanoma: a systematic review and meta-analysis of efficacy and review of characteristics. Expert Rev. Anticancer Ther. 2023 23 12 1281 1293 10.1080/14737140.2023.2278509 37908134
    [Google Scholar]
  89. Al-Suwayeh SA Taha EI Al-Qahtani FM Ahmed MO Badran MM Evaluation of skin permeation and analgesic activity effects of carbopol lornoxicam topical gels containing penetration enhancer. Scient. Worl. J. 2014 2014 127495 10.1155/2014/127495
    [Google Scholar]
  90. Guimarães K.L. Ré M.I. Lipid nanoparticles as carriers for cosmetic ingredients: The first (SLN) and the second generation (NLC). Nanocosme. Nanomed. 2011 101 122 10.1007/978‑3‑642‑19792‑5_5
    [Google Scholar]
  91. Tiwari N. Osorio-Blanco E.R. Sonzogni A. Esporrín-Ubieto D. Wang H. Calderón M. Nanocarriers for skin applications: Where do we stand? Angew. Chem. Int. Ed. 2022 61 3 e202107960 10.1002/anie.202107960 34487599
    [Google Scholar]
  92. Nikolić I. Simić M. Pantelić I. Stojanović G. Antić Stanković J. Marković B. Savić S. Chemical vs. physical methods to improve dermal drug delivery: A case study with nanoemulsions and iontophoresis. Pharmaceutics 2022 14 6 1144 10.3390/pharmaceutics14061144 35745717
    [Google Scholar]
  93. Singh B.N. Singh R.B. Singh J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum. Int. J. Pharm. 2005 298 1 98 107 10.1016/j.ijpharm.2005.04.004 15913928
    [Google Scholar]
  94. Herai H. Gratieri T. Thomazine J. Bentley M. Lopez R. Doxorubicin skin penetration from monoolein-containing propylene glycol formulations. Int. J. Pharm. 2007 329 1-2 88 93 10.1016/j.ijpharm.2006.08.021 17027205
    [Google Scholar]
  95. Simonetti L.D.D. Gelfuso G.M. Barbosa J.C.R. Lopez R.F.V. Assessment of the percutaneous penetration of cisplatin: The effect of monoolein and the drug skin penetration pathway. Eur. J. Pharm. Biopharm. 2009 73 1 90 94 10.1016/j.ejpb.2009.04.016 19442727
    [Google Scholar]
  96. Manconi M. Sinico C. Caddeo C. Vila A.O. Valenti D. Fadda A.M. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin. Int. J. Pharm. 2011 412 1-2 37 46 10.1016/j.ijpharm.2011.03.068 21530626
    [Google Scholar]
  97. Steluti R. Derosa F. Collett J. Tedesco A. Bentley M. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin. Eur. J. Pharm. Biopharm. 2005 60 3 439 444 10.1016/j.ejpb.2005.01.011 15996585
    [Google Scholar]
  98. Bugaj A. Juzeniene A. Juzenas P. Iani V. Ma L.W. Moan J. The effect of skin permeation enhancers on the formation of porphyrins in mouse skin during topical application of the methyl ester of 5-aminolevulinic acid. J. Photochem. Photobiol. B 2006 83 2 94 97 10.1016/j.jphotobiol.2005.12.003 16442808
    [Google Scholar]
  99. Bugaj A. Iani V. Juzeniene A. Juzenas P. Ma L.W. Moan J. The effect of dimethylsulfoxide, 1-[2-(decylthio)ethyl]azacyclopentan-2-one and Labrafac®CC on porphyrin formation in normal mouse skin during topical application of methyl 5-aminolevulinate: A fluorescence and extraction study. Photodiagn. Photodyn. Ther. 2006 3 1 27 33 10.1016/S1572‑1000(05)00109‑2 25049025
    [Google Scholar]
/content/journals/cis/10.2174/012210299X350515241208061724
Loading
Review Understanding of the many Facets of Cancer and the Management of Skin Cancer
Bentham Science Publishers , e2210299X350515; https://doi.org/10.2174/012210299X350515241208061724
/content/journals/cis/10.2174/012210299X350515241208061724
/content/journals/cis/10.2174/012210299X350515241208061724
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: Cancer ; Skin cancer ; Strategies ; Treatment ; Topical therapies ; Phytochemicals

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test